ArticleFrontiers in cellular and infection microbiology2021
Prediction of Prognosis in Adult Patients With Carbapenem-Resistant
Article in Frontiers in cellular and infection microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Resistance profile and influence factors of carbapenem-resistant Klebsiella pneumoniae (CRKP) causing infections in China: a systematic review and meta-analysis.Annals of clinical microbiology and antimicrobials · 2025Pooled it
- A nomogram for predicting 30-day mortality in patients with carbapenem-resistant Klebsiella pneumoniae infection: a retrospective cohort study.BMC infectious diseases · 2026Article
- Impact of loading dose β-lactam therapy on outcomes of KPC-producing Klebsiella pneumoniae bloodstream infections in non-ICU patients: a real world study.The Journal of antimicrobial chemotherapy · 2026Article
- Development and Validation of an Interpretable Machine Learning Model for Predicting Carbapenem-ResistantInfection and drug resistance · 2026Article
- Research article proteomics-based plasma biomarkers for predicting CRKP infection in ICU sepsis patients.Frontiers in pharmacology · 2026Article
- Frailty Index Laboratory (FI-Lab) as predictor of poor outcomes for intra-hospital multidrug-resistant Klebsiella pneumoniae bloodstream infections: a single-centre retrospective cohort study.The Journal of antimicrobial chemotherapy · 2025Article
- A Possible Tool for Guiding Therapeutic Approaches to Urinary Infections withAntibiotics (Basel, Switzerland) · 2024Article
- Resistance Genes and Mortality in Carbapenem-resistantBalkan medical journal · 2024Observational
- Prognostic Value of Computed Tomography-Measured Visceral Adipose Tissue in Patients with Pulmonary Infection Caused by Carbapenem-ResistantInfection and drug resistance · 2024Article
- Development of prediction models for carbapenem-resistantFrontiers in pharmacology · 2024Article
- Prognostic models for estimating severity of disease and predicting 30-day mortality of Hypervirulent Klebsiella pneumoniae infections: a bicentric retrospective study.BMC infectious diseases · 2023Article
- Molecular and Clinical Characteristics of Carbapenem-ResistantInfection and drug resistance · 2023Article
- Ceftazidime/Avibactam-Based Versus Polymyxin B-Based Therapeutic Regimens for the Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infection in Critically Ill Patients: A Retrospective Cohort Study.Infectious diseases and therapy · 2022Article
- Epidemic, risk factors of carbapenem-resistantFrontiers in cellular and infection microbiology · 2022Article
- Evaluation ofFrontiers in pharmacology · 2022Article
- Mortality-Related Risk Factors and Novel Antimicrobial Regimens for Carbapenem-Resistant Enterobacteriaceae Infections: A Systematic Review.Infection and drug resistance · 2022Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCarbapenem-resistant
methodsAdult patients diagnosed with CRKP infection in a tertiary hospital in Shanghai between September 2019 and March 2021 were included. The clinical characteristics and clinical outcomes of these patients were analyzed.
resultsA total of 199 cases of CRKP infection were examined. Five factors, namely age ≥65 years, respiratory failure, Sequential Organ Failure Assessment score, serum procalcitonin ≥5 ng/mL, and appropriate treatments in 3 days, were found to be associated with 30-day mortality. Upon incorporating these factors, the nomogram achieved good concordance indexes of 0.85 (95% confidence interval [CI]: 0.80-0.90) and well-fitted calibration curves. Receiver-operating characteristic curves for 7-, 15-, and 30-day survival had areas under the curve of 0.90, 0.87, and 0.88, respectively. Three-drug combination therapy was observed to be associated with lower mortality in the high-risk group (adjusted hazard ratio = 0.24, 95% CI: 0.06-0.99) but not in the low-risk group. Ceftazidime-avibactam, fosfomycin, and amikacin were effective against infections caused by CRKP. Tigecycline improved the treatment efficiency in 7 days, but a trend toward increased mortality was seen (HR, 1.69; 95% CI: 0.98-2.94;
conclusionThe antimicrobial regimen efficacy data and the predictive nomogram established in this study can help clinicians in identifying high-risk adult patients with CRKP infection, improving the therapeutic effect, and reducing mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.